This webinar reviewed statistical issues in the development and validation of gene signatures for breast cancer. Using three recently developed signatures (MammaPrint®, Oncotype DX® and MapQuant DxTM), the speakers discussed the role of gene selection, classification methods and cluster analysis in signature development, as well as the need for internal and external validation of the signatures.

Marc Buyse, S.c.D.

Marc Buyse, S.c.D.

Founder, Chief Executive Officer, and Chief Scientific Officer

Stefan Michiels, Ph.D.

Stefan Michiels, Ph.D.

Independent Statistical Consultant

Back to Resources

View the Presentation

Fields marked with an * are required.

When every data point represents a patient, accuracy and integrity aren’t optional — they’re everything. That’s why it’s IDDI.

Start Now